# OnCo record zongertinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zongertinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zongertinib" ;
  schema:name "Zongertinib"@en ;
  schema:description "Zongertinib was the first oral HER2 inhibitor for lung cancer with HER2 mutations, approved in 2025 and moved to first line in 2026."@en ;
  schema:url <https://onco.cc/drugs/zongertinib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Zongertinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (HER2)" ;
  schema:alternateName "Hernexeos" ;
  onco:approval "US 2025: HER2-mutant NSCLC, previously treated (accelerated)", "US 2026: First-line HER2-mutant non-squamous NSCLC" ;
  onco:acceleratedApproval "US 2025-08-08: Treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA approved test, and who have received prior systemic therapy", "US 2026-02-26: Treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test" ;
  onco:related <https://onco.cc/biomarkers/her2-mutation/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> ;
  onco:trials <https://onco.cc/trials/nct07195695/>, <https://onco.cc/trials/nct06324357/>, <https://onco.cc/trials/nct06581432/>, <https://onco.cc/trials/nct07486817/>, <https://onco.cc/trials/nct06151574/> .